sepsis

The Lexington, Massachusetts-based company has launched a two-hour SARS-CoV-2 test on its fully-automated instrument, the T2Dx.

The firm expects to validate its test as a triage tool to identify SARS-CoV-2 patients at risk of sepsis and pursue US FDA Emergency Use Authorization.

In December the firm won $4 million from CARB-X to support the platform's first test identifying the most common bloodstream infections associated with sepsis.

Of the 28 companies in the index, 21 firms saw their stock prices increase, while seven firms' share price decreased. 

he company said that it added 13 net new commercially contracted instruments globally, including 21 new contracts in the US.

In the quarter T2 signed a licensing agreement for SARS-CoV-2 assay development and a purchasing agreement with Vizient.

In October the company received $15 million in funding from BARDA and venture capital firms to advance its early sepsis detection technology.

The Swedish firms plans to launch clinical performance studies in support of getting CE marking for its QuickMIC system.